Inversago Pharma

Pioneering the development of first-in-class, peripherally-acting, CB1 inverse agonists

Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists.

The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as diabetic nephropathy, Non-Alcoholic Steatohepatitis (NASH), complications of obesity, hypertriglyceridemia (HTG) and Type 1 Diabetes (T1D), Prader-Willi Syndrome (PWS), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF).